The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Min Yuan1,2, Li-Li Huang1,2, Jian-Hua Chen1,3, Jie Wu3,4 and Qing Xu1,2

INTRODUCTION
Lung cancer is one of the most deadly and common types of cancer in the world.1 In 2018, there were over 1.7 million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer. Targeted therapy has emerged as an important mean of the disease management for patients with non-small-cell lung cancer (NSCLC). Herein, we review and analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer. Chemotherapy is no longer the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of the molecular features of patient’s tumor tissues. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy.

TARGETING PATHWAYS IN NON-SMALL-CELL LUNG CANCER
EGFR pathways
EGFR is a member of tyrosine kinase type I receptors family, and its gene is located on the short arm of human chromosome 7.24 In EGFR, there are 28 exons that form a protein that is distributed on the cell membrane of various epithelial cells, where it binds to epidermal growth factor or heparin-binding EGF and regulates the growth of cells.25 By comparison, exon 20 insertions and exon 18-point mutations are less common than exon 19 deletions and exon 21 L858R substitutions in terms of EGFR mutations in NSCLC.26,27 Activation and regulation of EGFR and downstream genes lead to cell proliferation, apoptosis, and angiogenesis.28 Some mechanisms have been used to target EGFR, such as tyrosine kinase inhibitors (TKIs), BRAF inhibitors.29,30 In past decades, tyrosine kinase inhibitors have been considered efficient drugs in NSCLC and have served as excellent targeted drugs.31 Various agents targeting EGFR have emerged out such as gefitinib, erlotinib, cetuximab and panitumumab.32

Mechanisms of drug resistance of EGFR pathways
EGFR TKIs (gefitinib and erlotinib) had substantial benefits in terms of PFS compared to chemotherapy as first-line therapy.35 Unfortunately, the OS in advanced NSCLC patients was not obviously affected by EGFR-TKI treatment after chemotherapy.36 Some studies have shown that patients develop drug resistance after receiving first-generation EGFR-TKI therapy for 10–14 months.37–38

Mechanisms of drug resistance in first-generation EGFR-TKI in addition, some studies have reported that some targeted therapies with immunotherapies are efficacious in NSCLC.23 Therefore, this review will focus on the gene mutations in important pathways in NSCLC, and discussed emerging therapies for these tumors (Fig. 1).

Signal Transduction and Targeted Therapy (2019)4:61 ; https://doi.org/10.1038/s41392-019-0099-9
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Yuan et al.

NSCLC have been identified such as TK domain mutation (T790M), MET amplification, RAS mutation. A subset of NSCLC patients with the T790M mutation have never undergone EGFR-TKI treatment. These findings suggest that the T790M mutation is a potential target in NSCLC patients. Therefore, new measures and therapies need to develop to overcome drug resistance.

In recent years, osimertinib has emerged as a third-generation EGFR-TKIs that can active and target both sensitive and resistant (T790M) EGFR mutations. In the FLAURA study, the median PFS of NSCLC patients treated with osimertinib (18.9 months) was obviously longer than that in patients treated with first-generation EGFR-TKIs (gefitinib and erlotinib) (10.2 months). This group of patients had EGFR exon 19 deletions or L858R mutations in untreated NSCLC that had progressed. Another study (AURA3) showed that the PFS associated with osimertinib was 10.1 months, whereas the PFS associated with pemetrexed/platinum doublet chemotherapy was 4.4 months. The objective response was obviously longer than that in patients treated with first-generation EGFR-TKIs in order to maximize their clinical benefit. Osimertinib followed by a first-or-second-generation EGFR-TKI or followed by pemetrexed/platinum doublet chemotherapy might be a rational choice. There remain debates about sequence of therapy, more clinical trials are required to clarify the most appropriate sequential therapy in patients with EGFR mutation-positive NSCLC.

Unfortunately, a study showed that drug resistance to osimertinib has emerged. Among 45 patients, the EGFR C797S mutation, mutations in PIK3CA, KRAS, BRAF, and MET amplification were found. In EGFR-mutated NSCLC, 5–20% EGFR-TKI drug-resistant patients developed MET amplification. MET amplification increases the proliferation and migration of HCC827 cell line in NSCLC. Results showed that targeting at MET amplification could prompt therapeutic efficacy. A MET inhibitor (crizotinib or SGX322) could increase the gefitinib sensitive in NSCLC. In addition, KRAS, a member of RAS mutation has been identified as the most frequently mutated oncogene in NSCLC. Previous studies have shown that KRAS mutation has been identified as a mechanism of EGFR-TKI resistance in NSCLC. Thus, therapeutic strategies target to KRAS mutation might be overcome drug resistance and improve the therapeutic efficiency. Some KRAS inhibitors have been identified, such as KRA$G12C mutant protein which showed excellent efficacy in vitro. Therefore, different therapeutic strategies targeting at EGFR pathway showed various efficacy which overcomes drug resistance and cancer progression.

PI3K/AKT/mTOR pathways

The PI3K/AKT/mTOR pathway is considered a potential target in NSCLC. The PI3K signaling pathway regulates various cellular processes, including cell proliferation, differentiation, and apoptosis, as well as gene transcription and protein synthesis. The PI3K/AKT/mTOR pathways has been demonstrated to activate upstream receptors (EGFR and PDGFR) and to be mutated in several cancers, including breast cancer, gastric cancer and NSCLC. Studies have shown that PIK3CA mutations occur in approximately 4% of NSCLC tumors expressing PTEN protein, which inhibits the PI3K/AKT/mTOR pathways. Several measures have attempted to target the PI3K/AKT/mTOR pathways in NSCLC. A PI3K inhibitor (LY294002) has been reported to enhance the sensitivity of NSCLC to chemotherapy and radiation. In addition, another mTOR inhibitor, temsirolimus (CCI-779), which targets molecules downstream of the PI3K pathways, has shown promising antitumor activity in phase I trials of NSCLC. Other PI3K/AKT/mTOR inhibitors, everolimus (RAD001 or AP23573), is also in preclinical trails. Studies have shown that downregulation of miR-93 in NSCLC inhibits cell proliferation and apoptosis. miRNA-223 has been shown to suppress cancer cells by targeting the EGFR/AKT2 pathway in NSCLC. Some studies have demonstrated that the PI3K/AKT/mTOR pathway is an important player in EGFR-TKI resistance. Loss of the PTEN gene, the protein product of which functions downstream of the PI3K/AKT/mTOR pathway, has been shown to play an important role in erlotinib and gefitinib resistance in EGFR-mutated NSCLC.

Several miRNAs have shown potential to reverse the PI3K/AKT/mTOR pathway-induced inhibition of tumor growth, progression,
and metastasis. Moreover, miRNAs can regulate resistance in NSCLC by targeting the PI3K/AKT/mTOR pathway. Wang C and colleagues demonstrated that miRNA-328 overexpression conferred cisplatin resistance to A549 cells via PTEN.20 Interestingly, an miRNA-328 inhibitor upregulated the expression of PTEN and restored the sensitivity to cisplatin in NSCLC cells.20 In addition, in Shen’s experiment, miR-21 was shown to have an important role in inducing gefitinib resistance in NSCLC.21 Knockdown of miR-21 by inhibiting the PTEN/PI3K/AKT pathways increased the sensitivity to gefitinib in vitro and in vivo.21 Han and colleagues demonstrated that miR-23a served as an inhibitor of PTEN in the PC9 NSCLC cell line.22 Downregulation of miR-23a reversed the resistance of erlotinib. Thus, miR-23a could be a potential target for overcoming resistance to EGFR-TKIs in NSCLC.23 In addition, there are several miRNAs that target the PI3K/AKT/mTOR pathways that have shown promising antitumor efficacy and the ability to reverse EGFR-TKIs resistance. Knockdown of miR-126, miR-203, and miR-34a has been demonstrated to regulate drug resistance via PI3K/AKT signaling.23-25 Furthermore, miRNAs can regulate upstream factors of the PI3K/AKT/mTOR pathways in NSCLC. The C-MET gene is known to be involved in resistance to EGFR-TKIs, and it was targetable by miR-34a in HCCB27 and PC-9 cells. miR-34a successfully inhibited the EGFR/PI3K/AKT pathway and reversed gefitinib resistance in NSCLC.26

The human RAS gene family, including KRAS, NRAS, and HRAS, encodes small plasma membrane G protein (GTPases) that regulate cell proliferation and progression through different pathways.27 Some upstream membrane receptors are associated with the RAS family, for example, EGFR and FGFR. In addition, some downstream pathways are involved (the RAS–MAPK and the PI3K–AKT–mTOR pathways) in cell differentiation and survival via the RAS family.29 The most mutated RAS family gene in lung cancer is KRAS.28 KRAS mutations occur in 20–40% of lung adenocarcinomas, which make up ~20% of cases in Western countries and ~10% of cases in Asian countries.29 Some studies have shown that KRAS mutations may be factors in EGFR-TKIs resistance in targeted therapies in NSCLC.29 Therefore, various agents attempt to target the RAS pathway in NSCLC to overcome drug resistance. Many downstream receptors of the RAS pathways, including RAF, MEK, and mTOR, have been studied as potential targets in NSCLC in multiple clinical trials. Sorafenib is an oral drug that serves as a multikinase inhibitor by targeting RAF and other receptors including VEGFR-2, VEGFR-3, and PDGFR-b.30 In early clinical trials, sorafenib showed promising efficacy and was well tolerated, with good stability in patients.82 However, in the subsequent clinical studies of sorafenib, the results showed that there was no efficacy in NSCLC, with objective response rates (ORRs) less than 10%.31,32 In addition, other BRAF inhibitors have shown similar results in clinical trials, performing well in BRAF-mutant patients but not KRAS-mutant lung NSCLCs.33 For MEK inhibitors, the results of clinical studies of selumetinib showed no benefit over pemetrexed-based chemotherapy in untreated NSCLC. Similar results have been found with trametinib when the therapy was compared with docetaxel chemotherapy.34 This lack of efficacy could be because current Raf inhibitors only recognize one binding site and thus decrease binding affinity for other sites. Thus, there is an urgent need for a method or new target drug to solve these problems in RAS-mutated patients. Several genetic methods have been developed and could be used to discover potential targets in NSCLC. Paula T. Hammond and colleagues tried to combine siKRAS, miR-34a and cisplatin to target the KRAS/PS3 mutation in NSCLC. Their results demonstrated that the combination of miRNA and chemotherapy enhanced the cancer cell line toxicity and increased the treatment efficacy, with a prolonged survival time in mice.35 Other studies showed that miR-202 enhanced the anti-tumor effect of cisplatin in NSCLC by targeting the Ras/MAPK pathway. In their study, the expression level of miR-202 was found to enhance the cisplatin sensitivity of NCI-H441 and A549 NSCLC cells. Furthermore, the overexpression of miR-202 was found to inhibit the Ras/MAPK pathway by targeting the KRAs gene.36 A similar phenomenon has been observed with other miRNAs, including miRNA-48a-3p and miR-193a-3p.37,38 In Liang Ma’s study, the researchers found that miR-148a-3p inhibited the development and progression of NSCLC by reducing the expression of SOS (son of sevenless) via Ras/MAPK/Erk signaling.39 In addition, decreased expression of miR-193a-3p was found in the NSCLC tumor tissues and inhibited cell proliferation and progression. In addition, the expression of miR-193a-3p was found to be associated with KRAS mRNA, which indicated that miR-193a-3p could act as a tumor suppressor by targeting KRAS in NSCLC.40

JAK–STAT pathways

Signal transducers and activators of transcription (STAT) proteins play a major role in a family of 7 different proteins (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6, and STAT7) that recruit Janus kinases (JAKs) by activating different proteins.39 The JAK–STAT pathways are involved and activated in various solid tumors, including NSCLC.40 The JAK–STAT pathways play important roles in cells differentiation, proliferation, and cancer progression. STAT3 is the most studied STAT family member and was found to play a role in malignancies of various types. In addition, in lung cancer, the STAT pathways regulates apoptotic genes, inhibits cell growth and improves the treatment efficacy of EGFR-TKIs.

Reports have indicated that combining EGFR-TKIs or chemotherapy with JAK/STAT pathway inhibitors could enhance antitumor efficacy and decrease drug resistance in NSCLC.42,43 The role of JAK/STAT pathway inhibitors in cisplatin resistance was studied in NSCLC cell lines and tumor xenograft models. The authors demonstrated that a JAK2 inhibitor (ruxolitinib) blunted the growth of cisplatin-resistant H1299 cells and enhanced antitumor activity by inhibiting tumor growth and inducing caspase-3 expression in tumor models with cisplatin resistance.44 However, further study of the efficacy and safety of combination treatments with JAK2 inhibitors is needed. Furthermore, Yibang Chen and his collaborators investigated the antitumor efficacy of a combination of a JAK-2 inhibitor (CYT387) and cetuximab in NSCLC models both in vitro and in vivo. The results demonstrated that cell toxicity increased when cetuximab was combined with CYT387 in resistant cell lines (H1975 and H1650). In addition, the antitumor activity was increased with the combination of a JAK/STAT pathway inhibitor with cetuximab in the resistant models. Thus, JAK–STAT pathway inhibitors could be a potential method in NSCLC therapy either alone or in combination with EGFR-TKIs.45 M. Li and his team studied the role of suppressor of cytokine signaling 3 (SOCS3) and miR-410 in regulating proliferation in NSCLC. SOCS3 negatively regulates the JAK–STAT pathways and was decreased in NSCLC tissue compared to normal tissue. They found that STAT3 phosphorylation was significantly reduced via treatment with anti-miR-410 and SOCS3 in lung cancer cells. These results indicate that miR-410 could serve a potential therapeutic target in NSCLC patients by regulating the JAK/STAT pathways. However, efficacy studies and clinical trials need to explore this potential in the future. Another study explored the potential role of miR-135 in NSCLC cells. The authors found that the expression of miR-135 was increased in NSCLC cells and that cell proliferation, invasion, and migration were suppressed with the silencing of miR-135. In addition, a subsequent study found that miR-135 inhibition upregulated TRIM16 expression through the JAK/STAT pathway and thus enhanced the sensitivity to gefitinib in NSCLC cell lines.46

Other measures attempt to enhance antitumor activity by combining a JAK/STAT inhibitor with gene therapy or immunotherapy. Manish R. Patel and his colleagues used a JAK/STAT...
inhibitor (ruxolitinib) in combination with vesicular stomatitis virus (VSV) to cure lung cancers. In their study, the results indicated that ruxolitinib increased the virotherapy efficacy in both resistant and sensitive NSCLC cells in vitro and in vivo. In addition, the combination therapy also enhanced PD-L1 expression and the levels of tumor immune infiltration in lung cancer.47 These results provide a method for NSCLC therapy, but further clinical evaluation of the combination of a JAK/STAT inhibitor with virotherapy or immunotherapy needs to be carried out.

HER3
Over the last two decades, it has become increasingly evident that HER3 plays an important role in cancer biology. HER3 (also known as ERBB3) is a unique member of the HER family and is considered an inactive receptor.52 EGFR and HER4 both have several ligands, while HER3 has only one single ligand, called heregulin (HRG) or neuregulin (NRG). Receptor interaction can result in dimerization when a ligand binds to the extracellular region of EGFR or HER3/4.49 Dimerization is the first critical step for HER receptor activation of downstream signaling pathways, such as the JAK/STAT, MEK/ERK, and PI3K/AKT pathways, and several others.50 To prevent dimerization, EGFR, HER3, and HER4 usually exist as molecularly folded monomers (inactive state).53 Unlike other HER family members (EGFR, HER2, and HER4), the HER3 receptor has little or no tyrosine kinase activity.54 Overexpression of HER3 can promote tumor progression by increasing metastatic potential in various human cancers and causing the failure of treatment. Studies have found highly activated HER3 with somatic mutations of EGFR in NSCLC.55 HER3 becomes potently trans-phosphorylated and activated by binding with mutated EGFR and mediates the PI3K/AKT pathway. Therefore, EGFR TKIs can achieve potent antitumor activity in EGFR-mutant NSCLC by preventing HER3/PI3K/AKT signaling activation.54 Even during ongoing EGFR-TKI therapy, HER3 can be activated by binding with an amplified MET oncogene, and this can perpetually activate the PI3K/AKT pathway.55 Thus, as a result of these characteristics of HER3 and its activity in cell survival signaling pathways, it might be a promising therapeutic target in EGFR-mutant NSCLC.

HER3 has been found to have an important role in resistance to EGFR-TKIs in NSCLC.56,57 Studies have revealed that an important mechanism resulting in resistance to EGFR-TKI therapy could be the compensatory upregulation of HER3 along with the sustained PI3K/AKT signaling.55,56,58 Because HER3 lacks kinase activity, targeting HER3 with a blocking antibody becomes a potential strategy being tested in current preclinical studies in cancer patients.60–62 Several phase I studies to evaluate monoclonal antibodies targeting HER3, such as patritumab, lumretuzumab, SAR256212 or LJM716, are ongoing. Results show acceptable safety of these agents either as monotherapies or in combination.54,63–66

U3-1287 (renamed as patritumab) was the first fully humanized anti-HER3 antibody. It has been examined in several clinical trials in patients with advanced solid tumors and is being currently studied in NSCLC.55,61 Patritumab has been shown in vitro and in vivo to overcome the HRG-dependent resistance to EGFR TKIs in NSCLC. These data further support the significance of ongoing clinical trials testing patritumab combined with EGFR-TKIs, such as erlotinib, to treat NSCLC patients with high expression of HRG.54 However, studies found that the antitumor activity of patritumab could be limited by combination treatment with erlotinib in patients with EGFR-TKI resistance acquired after therapy. A phase I clinical trial combining patritumab with erlotinib showed an overall response rate of 4.2% and a disease control rate of 62.5% in Japanese patients with advanced NSCLC.68 Similarly, a phase III study of patritumab combined with erlotinib in EGFR wild-type patients with locally advanced or metastatic NSCLC that had progressed on at least one prior systemic therapy was terminated.69 Thus, an alternative HER3-targeting therapy is required for EGFR-mutant NSCLC treatment.

U3-1402 is a new HER3-targeted antibody-drug conjugate with a fully human HER3-targeted antibody, a novel cleavable peptide-based linker, and a topoisomerase I inhibitor payload. There is an ongoing phase I trial of U3-1402 in patients with NSCLC.70 In a current study, it was reported for the first time that U3-1402 was an effective treatment for EGFR-mutant NSCLC.71 An ongoing multicenter phase I dose escalation and expansion study is assessing the safety/tolerability and preliminary activity of U3-1402 in metastatic or unresectable EGFR-mutant NSCLC patients who were T790M negative after disease progression while on erlotinib, gefitinib or afatinib, or who developed disease progression while on osimertinib regardless of T790M status.72 In 13 evaluable cases, all but one patient had a decrease in SLD, and two patients had confirmed the partial response. U3-1402 has shown preliminary antitumor activity and a manageable safety profile in EGFR TKI-resistant NSCLC.

**CLINICAL TRIALS ONGOING IN LUNG CANCER**
Molecular mechanism analysis revealed the targeted driver mutations in metastatic NSCLC patients. The treatment strategy of patients with metastatic NSCLC underwent significant transformation based on the molecular characteristics. Tyrosine kinase inhibitors (TKI) have provided an illustrative example of the successes in targeting oncogene addiction in lung cancer. Besides these targeted therapies, immune checkpoint inhibitors (ICI) to the treatment of metastatic NSCLC has dramatically changed the prognosis of selected advanced-stage patients. Suitable treatment options also need to explore through clinical trials to confirm.

EGFR/ALK TKIs
EGFR mutations are observed in 10–20% of patients not of East Asian descent with NSCLC and in approximately 40% of Asian patients.73 EGFR gene mutations mostly occur in adenocarcinomas, younger women and girls, and never-smokers,73,74 and are rarely identified in cases of lung cancer in smokers, which are usually more malignant than cases of lung cancer in nonsmokers.5

The first-generation reversible anti-EGFR tyrosine kinase inhibitors erlotinib and gefitinib were initially approved as second-line therapies in advanced patients after chemotherapy based on the many clinical trials that demonstrated their efficacy in some patients after initial lines of chemotherapy.76–80 They are now recommended as first-line therapies in advanced lung cancer patients with EGFR mutations.

Second-generation TKIs are a first-line therapy option for EGFR mutation-positive NSCLC. The LUX Lung 781 study compared afatinib with gefitinib in treatment-naive patients with activating EGFR mutations. The results exhibited improvements in PFS (HR = 0.73, 95% CI: 0.57–0.95, p = 0.017); the median PFS values were 11.0 and 10.9 months for the afatinib and gefitinib arms, respectively. However, grade 3–4 EGFR TKI-related toxicities, including skin rash, diarrhea, and stomatitis, were more common with afatinib than with gefitinib. Irreversible second-generation TKIs were developed with the intent to overcome these resistant tumor clones, but the associated clinical trials did not improve overall survival (OS) in T790M-mutant patients.82 In squamous cell lung cancer, EGFR mutations are rare. For advanced squamous cell lung cancer, the LUX Lung 8 phase III randomized controlled trial (N = 795) reported that afatinib improved PFS (2.6 vs 1.9 months, HR = 0.81, p = 0.0103) and OS (7.9 vs 6.8 months, HR = 0.81, p = 0.0077) compared with erlotinib as second-line therapy.84 The FDA and the European Medicines Agency have approved the use of afatinib in advanced squamous cell lung cancer patients after first-line chemotherapy.
More than 60% of patients develop resistance to first- or second-generation inhibitors. The common mechanism of acquired resistance to EGFR TKIs is the EGFR T790M mutation.85

Third-generation inhibitors were created to target the T790M clone while maintaining activity against the original exon19del and L858R mutations (Fig. 2). Osimertinib (AZD9291) is a third-generation tyrosine kinase inhibitor that has received accelerated approval by the FDA based on its targeting of the EGFR T790M mutation. Osimertinib initially gained FDA approval for patients with metastatic EGFR T790M-mutant NSCLC that had progressed on first- or second-generation EGFR TKIs and has subsequently gained approval as a first-line treatment of EGFR-mutant lung cancer. Other third-generation inhibitors are at various stages of development, and have not demonstrated superiority to osimertinib despite antitumor efficacy. Additional EGFR mutations have been detected during therapy. Mechanisms of resistance were also observed in the alternate pathways, such as EGFR amplification, hepatocyte growth factor (HGF) overexpression, FGFR2-FGFR1 loop mutations,86 MET amplification, PIK3CA mutations (E545K and E542K), PTEN loss, KRAS mutations, NRAS mutations, BRAF mutation, MAPK1/AKT3 overexpression, EGFR20 mutations, PIK3CA mutations, PTEN loss, KRAS mutations, NRAS mutations, BRAF mutation, MAPK1/AKT3 overexpression, FGFR2 mutations, PIK3CA mutations, PTEN loss, small cell histologic switch, fusion events.

Anaplastic lymphoma kinase (ALK) gene rearrangements are found in ~5% of patients with NSCLC and generally occur independently of EGFR and KRAS mutations, with a high risk of brain metastases.91-93 Third-generation tyrosine kinase inhibitors (TKIs) including crizotinib, ceritinib, and alectinib, have been approved by the FDA for the treatment of ALK-rearranged NSCLC patients.94 Crizotinib was the first ALK inhibitor, and acquired resistance to crizotinib is inevitable through several mechanisms.95-98 Second-generation (ceritinib, alectinib, crizotinib) and third-generation (lorlatinib) ALK inhibitors were developed. Alectinib is a second-generation ALK inhibitor and was shown to have high intracranial efficacy treating brain metastases.99-101 In ALK-rearranged patients, a variety of ALK resistance mutations can arise after treatment with crizotinib and other ALK inhibitors. To optimize treatment, combinatorial therapies with other targeted agents as well as combinations of ALK inhibitors with immunotherapy warrant further preclinical and clinical investigation.

Checkpoints inhibitors

Immunotherapy has changed the treatment landscape for cancer patients. Therapies targeting the programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) immune checkpoints have received approval across a wide range of tumor types, including NSCLC. Anti-PD-1/PD-L1 antibodies to treat metastatic NSCLC first entered the clinic in 2015 based on the CheckMate 017 trial.102 Then, pembrolizumab and atezolizumab also received regulatory approval in previously treated metastatic NSCLC patients.103,104 The results of CheckMate 032 have shown impressive response rates for the nivolumab and nivolumab/ipilimumab arms in relapsed small-cell cancer.105 However, immunotherapy is only effective for a small percentage of cancer patients, and the complexity of the tumor immune microenvironment may account for this phenomenon. Alternative immune checkpoints beyond PD-1/PD-L1 and additional therapies must be sought so that more patients can benefit from immune checkpoint therapy.

Several clinical trials using other immune checkpoint inhibitors in lung cancer are ongoing, such as trials of therapies targeting lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-containing Protein 3 (TIM-3), V-domain Ig suppressor of T cell activation (VISTA), human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2), and T cell Ig and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT).

Combination treatment strategies

As mentioned above, the clinical benefit of ICIs has been proven limited and unsatisfactory, with the overall response rate (ORR) of monotherapy about 10–20%. Current attempts to overcome this limitation include the development of predictive biomarkers and the introduction of combination therapies including ICIs. To improve the efficacy of the checkpoint inhibitor, lots of clinical trials with combination treatment therapy are emerged (Fig. 3).

**Checkpoint inhibitors combinations with a chemotherapy.** For those patients that lack driver mutations and high PD-L1 expression, platinum-based chemotherapy remains the standard
of care. The efficacy of chemotherapy is modest. Chemotherapy could induce PD-L1 expression on tumor cells and infiltrating immune cells. Immune checkpoint inhibitor therapies, harnessing the immune system, are demonstrating promising results in combination with chemotherapies.

The KEYNOTE-189 trial reported the results of a double-blind phase III study of chemotherapy in combination with pembrolizumab. This study showed significant improvement in the pembrolizumab arm: a median PFS 8.8 months vs. 4.9 months (HR, 0.52; 95% CI, 0.43–0.64) and an estimated OS of 69.2% vs. 49.4% at 12 months (HR, 0.49; 95% CI, 0.38–0.64). The survival benefit of combination therapy was evident in all subgroups, irrespective of age, sex, performance status, smoking status, brain metastases, PD-L1 expression, and type of platinum therapy used, although toxicity slightly increased. The double-blind, phase III KEYNOTE-407 study exhibited a similar finding in treatment-naive patients with metastatic squamous NSCLC. The combination of standard chemotherapy with immune checkpoint inhibitors could be a new strategy for first-line therapy in advanced stage NSCLC (Table 1).

Checkpoint inhibitors combinations with radiotherapy. There is evidence that radiotherapy (RT) combined with immunotherapy not only affects the local tumor microenvironment, but also improves systemic disease control. RT causes the release of tumor-related antigens and induces a release of some danger signals, such as HMGB1, ATP, and HSP90. There are several clinical trials exploring anti-PD-1/PD-L1 antibodies in combination with radiotherapy in NSCLC patients. In the KEYNOTE-001 phase I trial, it reported that the PFS with pembrolizumab was significantly longer in patients previously administered RT than in those not treated with RT. As a phase I trial, pembrolizumab was administered at different doses and treatment deliveries. There have been results from phase I, phase II, or phase III (RTOG 3505) and beyond studies, and the results of the RTOG 3505, which evaluated chemoradiation followed by nivolumab therapy or placebo in locally advanced NSCLC patients in terms of OS, PFS, and toxicity are pending.

Checkpoint inhibitor combinations with EGFR TKI strategies. Patients treated with EGFR TKIs eventually develop acquired resistance. It has been reported that activation of the oncopgenic EGFR pathway enhances the susceptibility of lung cancers to PD-1 blockade in mouse models, suggesting that combination of PD1 blockade with EGFR TKIs may be a promising therapeutic strategy. As part of the CheckMate 012 study, nivolumab combined with erlotinib exhibited grade 3 toxicities in 19% of patients. The combination of osimertinib plus durvalumab (phase Ib TATTON trial (NCT02143466)) in pretreated or chemotherapy-naive NSCLC patients showed encouraging clinical activity; however, this combination was associated with a high incidence of diarrhea (53% grade ≥ 3) in the osimertinib arm and rash (67%) in the combination arm. Treatment-related grade 3–4 adverse events were observed with the combination therapy. Given the relatively high incidence of treatment-related toxicities associated with the combination of the EGFR TKI and immunotherapy, the combination of the EGFR TKI and immunotherapy should be further investigated.

Checkpoint inhibitors (anti-PD-L1/PD-1) combinations with anti-CTLA-4. Strategies combining checkpoint inhibitors with other immune modulatory agents are promising. Combinations with anti-PD-1 or anti-CTLA-4 therapies are being explored in NSCLC as first- and second-line therapies. The CheckMate 012 trial evaluated both the safety and efficacy of nivolumab in combination with ipilimumab as a first-line therapy in advanced NSCLC patients. In these patients (n = 77), grade 3–4 treatment-related AEs occurred in 37% of patients (14 patients) in the group that received ipilimumab every 12 weeks. After a follow-up of 12.8 months, the ORR values were 47 and 38%, respectively. After 2 years of follow-up, the pooled results from both cohorts showed that continued clinical benefit was observed with nivolumab plus
### Table 1. Combinations of checkpoint inhibitors with chemotherapy in clinical trials.

| Checkpoint inhibitors | Chemotherapy                        | Patients enrolled | Clinical setting                                                                 | Phase | NCT numbers     | status          | Estimated completion date |
|----------------------|-------------------------------------|------------------|---------------------------------------------------------------------------------|-------|-----------------|----------------------|---------------------------|
| Nivolumab            | Docetaxel                           | 664              | Advanced NSCLC with disease progression on or after platinum-Based Chemotherapy | III   | NCT03906071     | Recruiting        | December 2022           |
| Nivolumab + Ipilimumab | Platinum-based chemotherapy + Nivolumab | 112              | Chemonaive metastatic or recurrent squamous-cell lung cancer (SqLC)            | II    | NCT03823625     | Recruiting        | February 2021            |
| Atezolizumab         | Vinorelbine                         | 71               | Second-line treatment for patients with stage IV non-small cell lung cancer     | II    | NCT03801304     | Recruiting        | July 2022                |
| Trilacilib + Atezolizumab | Carboplatin + Atezolizumab | 105              | Untreated extensive stage small cell lung cancer                              | II    | NCT03041311     | Active, not recruiting | May 2020                |
| Nivolumab            | Tetrahydrouridine                   | 13               | Second line therapy for non-small cell lung cancer                            | II    | NCT02664181     | Completed         | July 2019               |
| M7824 + temozolomide | M7824 + topotecan                   | 57               | Relapsed small cell lung cancers                                              | I/II  | NCT03554473     | Recruiting        | January 2024            |
| Nivolumab            | Carboplatin/paclitaxel or carboplatin/pemetrexed | 192          | Metastatic or advanced non-small cell lung cancer (NSCLC)                      | I     | NCT02944396     | Active, not recruiting | October 2019            |
| Nivolumab            | standard chemo-radiotherapy         | 94               | Locally advanced stage iii/b non-small cell lung carcinoma                     | II    | NCT02434081     | Active, not recruiting | August 2020             |
| Nivolumab, Ipilimumab| Carboplatin, Paclitaxel, Pemetrexed, Cisplatin | 700           | First line therapy in stage IV non-small cell lung cancer                      | IV    | NCT03215706     | Recruiting        | November 2020           |

### Table 2. Combinations of checkpoint inhibitors in clinical trials.

| Checkpoint inhibitors | Patients enrolled | Clinical setting                                                                 | phase | NCT numbers     | status          | Estimated completion date |
|----------------------|------------------|---------------------------------------------------------------------------------|-------|-----------------|----------------------|---------------------------|
| Nivolumab + Ipilimumab | 1100             | Advanced NSCLC                                                                  | IV    | NCT02869789     | Recruiting        | June 2020                |
| Nivolumab + Ipilimumab | 50              | Anti-PD-1-axis therapy-resistant advanced non-small cell lung cancer            | II    | NCT03262779     | Recruiting        | November 2020            |
| Nivolumab + Ipilimumab + Nintedanib | 98       | Non small cell lung cancer                                                     | I/II  | NCT03377023     | Recruiting        | February 2021            |
| Nivolumab + Ipilimumab | 108             | After concurrent chemoradiation in patients with unresectable stage III NSCLC | II    | NCT03285321     | Recruiting        | September 2022           |
| Pembrolizumab + Ipilimumab | 57      | Advanced NSCLC/extensive-disease small cell lung cancer (MK-3475-011/KEYNOTE-011) | I     | NCT01840579     | Active, not recruiting | June 2020                |
| Nivolumab + Ipilimumab | 504             | Advanced non-small cell lung cancer (FRACTION-Lung)                             | II    | NCT02750514     | Active, not recruiting | April 2021               |
| Nivolumab + Ipilimumab | 30              | Resectable non-small-cell lung cancer                                          | II    | NCT02259621     | Recruiting        | January 2023             |
| Nivolumab + Ipilimumab | 24              | Pretreated advanced stage non-small cell lung cancer patients                   | I     | NCT03509584     | Not yet recruiting   | April 2021               |
TREATMENT ADVANCE OF TARGETED THERAPY IN NON-SMALL CELL LUNG CANCER

Since the targeted therapy was well developed, chemotherapy was no longer the most important treatment for advanced and metastatic NSCLC patients. Meanwhile, chemotherapy cannot differentiate tumor cells and normal cells while working, the treatment-related adverse reactions are dramatically strong therefore being feared by patients. The molecularly targeted therapies with less adverse reactions have prolonged disease control, and ultimately improved long-term survival outcomes in NSCLC patients.

First-line therapy

EGFR-TKIs. EGFR gene sensitivity mutations are the most important discovery in the clinical research of lung cancer in the 21st century. The EGFR gene is one of the most well-studied molecular targets driving lung cancer, and EGFR-targeted therapy has been applied to all stages of advanced NSCLC.

Japanese researchers first used gefitinib in 16 patients with EGFR gene sensitivity mutations, with an effective rate of 75%.12 This opened the era of phase III clinical research for targeted therapy in patients with EGFR gene sensitivity mutations. The results of the IPASS, NEJGSG, WJOTG3405, First-SIGNAL, OPTIMAL, EURTAC and LUX-Lung3 trials all showed that patients with EGFR gene sensitivity mutations who were treated with TKIs were significantly better than traditional platinum-containing chemotherapy in the first-line setting.80,113–117 For EGFR-mutated NSCLC patients, EGFR-TKIs have a significant advantage in terms of PFS, quality of life and tolerance, thus establishing the role of EGFR-TKIs in first-line setting in advanced EGFR-mutated NSCLC patients.

Osimertinib is a third-generation, irreversible EGFR-TKI that can selectively inhibit both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. The EGFR T790M mutation is the most common mechanism of acquired EGFR resistance; however, the same mutation on both alleles is also present in 1–8% of patients with NSCLC, which may imply a poorer prognosis.118 Due to the positive results of the AURA clinical trial, osimertinib has been approved to treat T790M-positive NSCLC patients who have disease progression after EGFR-TKI therapy.119–121 In a phase III trial (FLAURA), gefitinib and erlotinib are being compared to osimertinib in previously untreated patients with EGFR-mutant NSCLC. In total, 556 patients were assigned in a 1:1 ratio to receive either osimertinib or a standard EGFR-TKI. In January 2018, it was announced that osimertinib showed superior efficacy over standard EGFR-TKIs, and it also showed a significantly prolonged median progression-free survival compared with standard EGFR-TKIs (18.9 months vs. 10.2 months).122 NCCN oncology clinical practice guidelines recommend osimertinib for the first-line treatment of advanced or metastatic EGFR-mutated NSCLC patients (IA).123 In April 2018, The US Food and Drug Administration (FDA) approved osimertinib as a first-line treatment for patients with metastatic EGFR-mutant NSCLC.124 The FLAURA trial has clearly established osimertinib as a well-tolerated and effective systemic therapy for advanced EGFR mutant NSCLC in the first-line setting. Despite its robust first-line efficacy, further research is needed to determine which sequence of EGFR TKIs will ultimately provide the greatest duration of disease control, the longest overall survival, and the best quality of life. Additionally, as further insights into new treatments for acquired resistance to third-generation EGFR inhibitors emerge, the place of osimertinib in therapeutic strategies may continue to evolve.

EGFR-TKIs enable patients to achieve superior survival, but currently, the efficacy of monotherapy has reached a bottleneck. Targeted therapy combined with anti-angiogenic drugs can improve the tumor microenvironment, which may be a better treatment plan. In a phase II trial (BELIEF), the combination therapy of erlotinib and bevacizumab was evaluated in previously untreated patients. The median progression-free survival was 16 months in the T790M-positive subgroup.125 A phase II study (JO25567) was undertaken in Japan to compare erlotinib alone with erlotinib plus bevacizumab, as a first-line therapy in patients with advanced EGFR-mutant NSCLC. This study found that the PFS was longer with the combination treatment than with erlotinib monotherapy (HR = 0.54, p = 0.0015).126 A subsequent confirmatory phase III study (NEJ 026) was designed to compare erlotinib with erlotinib plus bevacizumab, in patients with untreated EGFR-mutated NSCLC. It showed that the median PFS was 13.3 months compared to 16.9 months (HR = 0.605, p = 0.016).127 Therefore, bevacizumab plus erlotinib has become a new standard therapy for treatment-naive patients with EGFR-mutated NSCLC.

PD-1 targeted immunotherapy as first-line therapy. The proportion of patients who have mutations in driver genes in NSCLC is not high. It accounts for only about 30% of the Western population. The proportion of adenocarcinomas in the Chinese population is higher than that in the Western population, but ~40% of these patients still do not have mutations in driver genes.128,129 Platinum-based doublet chemotherapy regimens remain the cornerstone of treatment for patients with recurrent or metastatic NSCLC without EGFR mutations or ALK translocations.130 Human immune checkpoint inhibitor (ICI) antibodies can inhibit the PD-1 receptor or PD-L1 and improve antitumor immunity.130,131 The PD-1/PD-L1 signaling pathway plays an important role in NSCLC. Lung tumor tissue samples obtained from patients with treatment-naive, advanced NSCLC have demonstrated a high level of PD-L1 expression (TPS ≥ 50%) in ~30% of patients.132,133 The Phase III study (KEYNOTE-024) compared pembrolizumab monotherapy with standard platinum-based chemotherapy in adult patients (≥18 years) with previously untreated advanced NSCLC.134 305 patients were randomly assigned to two arms (pembrolizumab, n = 154; chemotherapy, n = 151). The median OS was 30.0 months with pembrolizumab (95% CI, 18.3 months to not reached) and 14.2 months with chemotherapy (95% CI, 9.8 to 19.0 months). There were less treatment-related grade 3–5 adverse events with pembrolizumab than with chemotherapy (31.2 vs 53.3%). Due to the confirmed favorable benefit-to-risk profile of PD-1 inhibition, the FDA and EMA have approved pembrolizumab monotherapy for the first-line treatment of patients with metastatic NSCLC whose PD-L1 TPS is ≥50%, with no EGFR or ALK mutation.135 Immune checkpoint blockades have displayed great potential in cancer therapy and have exhibited a remarkable efficacy compared to conventional treatments for advanced NSCLC. However, not all patients benefit from these agents. Equally important, the development of resistance to anti-PD-1/PD-L1 immunotherapy can lead to the failure and poor prognosis in advanced NSCLC patients. The mechanism underlying the resistance is not fully understood. In addition, little is known about the role of varying levels of PD-L1 positivity, the potential antigen load or mutational load in the tumor, and genetic determinants in the efficacy and resistance associated with anti-PD-1/PD-L1 therapy.

Subsequent therapy

Because the line of therapy can vary depending on previous treatment with targeted agents, the phrase subsequent therapy has been recently substituted for the terms second-line systemic therapy, third-line systemic therapy, and beyond. Subsequent
therapy for patients who have disease progression during or after first-line therapy mostly depend on the specific genetic alteration and the histologic subtype.

Most patients who undergo an initial treatment with first- or second-generation EGFR-TKIs develop resistance and disease progression within a median of 10–12 months. Therefore, third-generation EGFR-TKIs, such as osimertinib and rociletinib, which can selectively target T790M mutants, were developed as second-line treatment options for these patients. The clinical trials of osimertinib included the AURA phase I, AURA extension phase, AURA2, and AURA3 studies, which supported the efficacy of these agents in T790M-positive advanced NSCLC patients, who had progressed after first- or second-generation EGFR-TKIs. Nivolumab is the first immune checkpoint inhibitor (ICl) approved for the second-line treatment of NSCLC. A phase II trial (CheckMate-063) evaluated the efficacy and safety of nivolumab in patients with advanced NSCLC. The ORR was 14.5%, with a median OS of 8.2 months, and a 1-year survival rate of 40.8%. Another two phase III trials (CheckMate-017 and CheckMate-057) were decisive in recommending immunotherapy for the patients of NSCLC. These studies supported the effectiveness of nivolumab in the second-line setting.

One large randomized phase IIb/III trial (KeyNote-010) enrolled 1034 pretreated patients with advanced NSCLC with PD-L1 expression in at least 1% of tumor cells. The OS was significantly prolonged with pembrolizumab versus docetaxel. In a recent update of this trial, the 36-month survival rate was 26.4% (95% CI 14.3–40.1) for untreated patients and 19.0% (15.0–23.4) for previously treated patients. Atezolizumab is a humanized IgG1 monoclonal antibody against PD-L1. The POPLAR study was designed to compare atezolizumab with docetaxel. The results showed the median OS was 12.6 months compared to 9.7 months, respectively (HR 0.73, 95% CI 0.53–0.99; p = 0.04). The 3-year OS rate was 18.7% vs 10%, respectively. Additionally, the OAK study was a phase III trial that enrolled 1,225 pretreated NSCLC patients who were randomized to receive atezolizumab or docetaxel. The median OS was 13.8 months vs 9.6 months, respectively (HR 0.73, 95%CI 0.62–0.87; p = 0.0003).

Maintenance therapy

Maintenance therapy is usually used to slowdown the growth of advanced cancer after the initial treatment. It includes two situations: continuation maintenance and switch maintenance. Continuation maintenance chooses one or more drugs which have been used in the first-line therapy. Switch maintenance, also known as early second-line, uses an additional agent after the first-line chemotherapy. Paclitaxel was the first chemotherapeutic agent tested as maintenance therapy. Approval of erlotinib in the maintenance setting for locally advanced or metastatic NSCLC was based on the results of the randomized, multicenter, placebo-controlled phase III SATURN trial. In this study, ~2000 patients were randomized to placebo or maintenance erlotinib after platinum-based chemotherapy. After a median follow-up of 11 months, erlotinib showed a statistically significant but very small advantage in PFS (3.0 vs 2.8 months). In addition, patients with EGFR-mutated adenocarcinoma obtained the greatest outcome benefit. The INFORM study confirms that patients receiving EGFR-TKIs as maintenance or subsequent treatment have longer OS than patients who have never received any EGFR TKIs. The positive results from the INFORM trial demonstrate that gefitinib in the maintenance setting leads to significantly improved outcomes for patients with EGFR-mutated advanced NSCLC.

In contrast, a randomized, double-blind, phase III trial (IUNO) demonstrated that, no OS benefit was observed for maintenance erlotinib versus second-line erlotinib treatment in patients with advanced NSCLC without EGFR-activating mutations. Subgroup analyses of OS based on stratification factors, demographics, or baseline characteristics provided results that were consistent with those for the overall population. Based on the lack of benefit observed in this trial, maintenance treatment with erlotinib is no longer considered to be superior in patients with advanced or metastatic NSCLC without EGFR mutation. The maintenance indication is being revised, and maintenance therapy with erlotinib should only be considered for patients with locally advanced or metastatic EGFR-mutated NSCLC. Using bevacizumab or pemetrexed as continuation maintenance is an option in patients with nonsquamous NSCLC and negative or unknown EGFR mutation status, ROS1 rearrangements, ALK rearrangements, or PD-L1 expression in less than 50%. A randomized study (ECOG 4599) enrolled 878 patients with recurrent or advanced NSCLC and compared chemotherapy with chemotherapy plus bevacizumab. The median survival was 10.3 vs 12.3 months (hazard ratio for death, 0.79; p = 0.003). The median progression-free survival in the two groups was 4.5 vs 6.2 months (hazard ratio for disease progression, 0.66; P < 0.001). The POINTBREAK study reported a very slight improvement in PFS (6 vs 5.6 months) when comparing bevacizumab plus pemetrexed versus bevacizumab alone as maintenance therapy. Similarly, the AVAPERL study using bevacizumab plus pemetrexed versus bevacizumab alone as maintenance therapy, showed a 3.7-month increase in PFS (7.4 vs 3.7 months). A phase III trial (ATLAS) evaluated bevacizumab with or without erlotinib, after bevacizumab combined with chemotherapy for the first-line treatment of advanced NSCLC. The results showed that the addition of erlotinib to bevacizumab significantly improved PFS (4.8 vs 3.7 months) but not OS (14.4 vs 13.3 months). The slight impact on survival and increased toxicity of erlotinib combined with bevacizumab indicate that this two-drug maintenance regimen will not be a new standard therapy.

In summary, maintenance therapy is a new treatment option for advanced NSCLC patients with no additional significant side effects beyond those first-line chemotherapy, no significant comorbidities and good PS. The impacts on QoL and economic aspects for patients should be further considered. Predictive factors are needed to select patients who may benefit from maintenance therapy.

Adjuvant therapy

Targeted therapy in early-stage NSCLC. Nearly a third of NSCLC patients have potentially curable early-stage disease. Adjuvant cisplatin-based doublet chemotherapy has been shown to improve overall survival in patients with stage I-II NSCLC. A meta-analysis named Lung Adjuvant Cisplatin Evaluation (LACE) was conducted to gain a comprehensive understanding of the benefits of adjuvant chemotherapy. The LACE meta-analysis enrolled 4584 patients and had a median follow-up of 5.2 years. The results confirmed a 5.4% overall survival (OS) benefit with adjuvant chemotherapy compared to observation at 5 years (HR = 0.89, 95% CI = 0.82–0.96). A Cochrane meta-analysis by Burdett et al. also confirmed the benefit of adjuvant chemotherapy in early-stage NSCLC.

To assess the role of targeted agents in adjuvant therapy, several clinical trials are ongoing. The RADIANT study was designed to evaluate the efficacy of erlotinib as an adjuvant treatment in patients with resected NSCLC. The INFORM study confirmed that patients receiving EGFR-mutated adenocarcinoma obtained the greatest outcome benefit. The RADIANT study support the need for further adjuvant trials in patients selected by biomarker status. However, a recently presented analysis showed no disease-free survival benefit with erlotinib in patients with EGFR mutations, with an HR of 0.75 (95% CI 0.38–0.91, p = 0.039). This difference, however, was not significant according to the statistical design. The results from the RADIANT trial support the need for further adjuvant trials in patients with stage IA–IIA EGFR-mutant NSCLC. Only two
patients recurved during erlotinib therapy among the 24 patients who had disease recurrence. The 2-year disease-free survival was 90%, which was higher than the expected rate of 72%. The authors commented that the patients who had disease recurrence had a significantly shorter duration of treatment. Therefore, a longer duration of targeted adjuvant treatment may be beneficial for patients after surgery. Since it was a single-arm study, caution needs to be exercised when interpreting the results. Recently, a phase III trial (CTONG1104) was reported. In this study, patients with resected stage II–III NSCLC with EGFR or ALK mutations were randomized to either gefitinib for 2 years or vinorelbine plus cisplatin for four cycles. After a median follow-up of 36.5 months, the gefitinib group had a significantly higher median disease-free survival than vinorelbine plus cisplatin group (28.7 months vs 18 months, HR 0.6, 95% CI 0.42–0.87, p = 0.005). Disease-free survival was significantly better with gefitinib at 3 years than with vinorelbine plus cisplatin (34% vs. 27%, p = 0.013). Since the data are not yet complete, the OS results have not been reported.

In summary, the available data suggest that adjuvant therapy using EGFR-TKIs could improve PFS, but this advantage has not been translated into prolonged OS. This finding might suggest reason why EGFR-TKIs are unable to eliminate disease with micrometastases.

Important ongoing trials. The ALCHEMIST trial, which is also named the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial, is sponsored by the National Cancer Institute (NCI). To identify and screen patients with EGFR and ALK mutations in early-stage, resected, nonsquamous NSCLC, the study was designed by using an umbrella design (Fig. 4). Up to August 2018, there had been 309 patients enrolled in the screening trial. The ALCHEMIST trial will answer the question of whether targeted therapy can be part of curative care in NSCLC, and will provide more tumor samples for genomic analysis, which may be an opportunity to advance the understanding of the disease biology.

Adjuvant and neo-adjuvant immunotherapy trials. Checkpoint inhibitors targeting the PD1/PD-L1 axis, such as pembrolizumab, nivolumab, and atezolizumab, have completely changed the landscape of treatment in advanced or metastatic lung cancers. Given the promising results seen in the advanced or metastatic diseases settings, these agents are now being assessed as adjuvant treatments in early-stage NSCLC.

The ALCHEMIST-nivo (EA5142; NCT02595944) study is one arm of the ALCHEMIST trial, in this study, patients without EGFR or ALK mutations will be randomized to adjuvant nivolumab versus observation for up to 1 year. A global phase III randomized trial (IMpower101, NCT02486718), is being conducted to evaluate the efficacy and safety of atezolizumab versus best supportive care in patients with resected stage IB–IIIA NSCLC following adjuvant cisplatin-based chemotherapy. Another phase III study (PACIFIC) will compare the PD-L1 inhibitor durvalumab versus placebo in unresectable stage III NSCLC patients following chemoradiation adjuvant therapy. The interim analysis of the PACIFIC trial has reported a median PFS of 16.8 (durvalumab) vs 5.6 months (placebo), with an HR of 0.52 (95% CI 0.42–0.65, p < 0.001). The results of this study provide hope for checkpoint inhibitors as adjuvant therapy in patients with resected NSCLC.

CONCLUSIONS AND FUTURE PERSPECTIVE

In summary, targeted therapies and immunotherapies have changed NSCLC treatment. There have been great advances in lung cancer diagnosis using molecular and immunological methods and theories. In addition to epidermal growth factor receptor (EGFR), new molecular targets are being continuously detected, such as microRNAs, HER3 and immune checkpoint receptor (EGFR), new molecular targets are being continuously detected, such as microRNAs, HER3 and immune checkpoint inhibitors, prompting the development of new therapies. Many clinical trials for the agents of targeted therapy and immunotherapy are ongoing and have shown promising and exciting results to date. These trials will help to define the role of targeted therapy in the treatment of lung cancer, including the role of immune monotherapies, combination immunotherapies, and combinations of targeted therapies with immunotherapies, as well as the ideal timing of these therapies and whether they should be used in early-stage versus late-stage disease. Targeted therapy may ultimately change the treatment paradigm for lung cancer, providing hope for patients with limited treatment options. The search of predictive factors of response to targeted drugs remains an important issue of clinical research. Future combination
therapies (either targeted therapies or immunotherapies) and better understanding of molecular biomarkers could lead to the ultimate curative option.

ACKNOWLEDGEMENTS
The authors would like to acknowledge financial support by grants from the Shengkang Clinical Three-Year Action Plan (no. 16C30728), the Key Project of Shanghai Health and Family Planning Commission (no.201640020), the Western Medicine Guideing Project of Shanghai Science and Technology Commission (no.17111967300), the Shanghai Municipal Commission of Health and Family Planning Research and Development of New Chinese Medicine and Hospital Preparations (no.2016L029), the Shanghai Science and Technology Commission, Industry-University-Research Subproject (no.16431903200), the Shanghai Sailing Program (no. 19PY1438300), the Pujiang Fostering Program of Shanghai Tenth Peoples' Hospital (no.040118004), the National Natural Science Foundation of China (no. 81803090 and 81772905), and the Shanghai outstanding academic leader (no.19YF1438300).

ADDITIONAL INFORMATION
Competing interests: The authors declare no competing interests.

REFERENCES
1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer Statistics, 2017. CA Cancer J. Clin. 67, 7–30 (2017).
2. Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108 (2015).
3. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386 (2015).
4. Halliday, P. R., Blakely, C. M. & Bivona, T. G. Emerging targeted therapies for the treatment of non-small cell lung cancer. Curr. Oncol. Rep. 21, 21 (2019).
5. Politi, K. & Herbst, R. S. Lung cancer in the era of precision medicine. Clin. Cancer Res. 21, 2213–2220 (2015).
6. Herbst, R. S., Morgensztern, D. & Boshoff, C. The biology and management of non-small cell lung cancer. Nature 533, 446–454 (2016).
7. Singh, S. S., Dahal, A., Sheehata, L. & Jois, S. D. Genotype driven therapy for non-small cell lung cancer: resistance, pan inhibitors and immunotherapy. Curr. Med. Chem. http://www.eurekaselect.com/170183/article (2019).
8. Hay, N. & Sonenberg, N. Upstream and downstream of mTOR. Genes Dev. 18, 1926–1945 (2004).
9. Beeser, C. S., Li, F., Liu, L. & Huang, S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int. J. Cancer 119, 757–764 (2006).
10. Liu, X. L. et al. INSG knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/Pi3K/Akt and IL-6/STAT3 signaling pathways. Oncotarget 8, 54265–54276 (2017).
11. Kawano, O. et al. Pi3kca mutation status in Japanese lung cancer patients. Lung Cancer 54, 209–215 (2006).
12. Song, Z., Yu, X. & Zhang, Y. Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma. Cancer Med. 5, 2694–2700 (2016).
13. Brognard, J., Clark, A. S., Ni, Y. & Dennis, P. A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 61, 3986–3997 (2001).
14. Hidalgo, M. et al. A phase I and pharmacokinetic study of temsirolimus (CC-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin. Cancer Res. 12, 5755–5763 (2006).
15. Li, C., Lyu, J. & Meng, Q. H. MIR-93 promotes tumorigenesis and metastasis of non-small cell lung cancer cells by activating the PI3K/Akt pathway via inhibition of LKB1/PTEN/CDKN1A. J. Cancer 8, 870–879 (2017).
16. Ma, H. P. et al. miRNA-223 is an anticancer gene in human non-small cell lung cancer through the PI3K/Akt pathway by targeting EGFR. Oncol. Rep. 41, 1549–1559 (2019).
17. Fumalora, C., Bonelli, M. A., Petronini, P. G. & Alferi, R. R. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol. 90, 197–207 (2014).
18. Fresno Vara, J. A. et al. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 30, 193–204 (2004).
19. Perez-Ramirez, C. et al. PTEN and PI3K/AKT in non-small-cell lung cancer. Pharmacogenomics 16, 1843–1862 (2015).
20. Wang, C., Wang, S., Ma, F. & Zhang, W. miRNA328 overexpression confers cisplatin resistance in nonsmall cell lung cancer via targeting of PTEN. Mol. Med. Rep. 18, 4563–4570 (2018).
21. Shen, H. et al. Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer. PLoS ONE 9, e103305 (2014).
22. Han, Z. et al. Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway. Oncol. Rep. 38, 3064–3070 (2017).
23. Garofalo, M. et al. EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat. Med. 18, 74–82 (2011).
24. Zhao, J. et al. Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer. Lung cancer 108, 96–102 (2017).
25. Zhang, M., Ma, X., Sun, C. & Chen, L. MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer. Chem.-Biol. Interact. 184, 431–438 (2010).
26. Zhou, J. Y. et al. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. Cancer Lett. 351, 265–271 (2014).
27. Downward, J. Targeting Ras signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11–22 (2003).
28. Ricciuti, B. et al. Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. Expert Rev. Respir. Med. 10, 53–68 (2016).
29. Massarelli, E. et al. KRAS mutation is an important predictor of resistance to therapy with epithelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res. 13, 2890–2896 (2007).
30. Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099–7109 (2004).
31. Blumenschein, G. R. Jr. et al. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin. Cancer Res. 19, 6967–6975 (2013).
32. Papadimitriakopoulou, V. et al. The BATTLE-2 Study: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 34, 3638–3647 (2016).
33. Ferrer, I. et al. KRAS-Mutant non-small cell lung cancer: From biology to therapy. Lung Cancer 124, 53–64 (2018).
34. Blumenschein, G. R. Jr. et al. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) patients. Ann. Oncol. 26, 894–901 (2015).
35. Gu, L., Deng, Z. J., Roy, S. & Hammond, P. T. A Combination RNAi-chemotherapy layer-by-layer nanoparticle for systemic targeting of KRAS/P53 with cisplatin to treat non-small cell lung cancer. Clin. Cancer Res. 23, 7312–7323 (2017).
36. Sun, W. et al. miR-202 enhances the anti-tumor effect of cisplatin on non-small cell lung cancer by targeting the Ras/MAPK pathway. Cell. Physiol. Biochem. 51, 2160–2171 (2018).
37. Xie, Q. et al. microRNA-148a-3p inhibited the proliferation and epithelial-mesenchymal transition progression of non-small-cell lung cancer via modulating Ras/MAPK/Erk signalling. J. Cell. Physiol. 234, 12786–12799 (2018).
38. Mir-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRAS.pdf.
39. The role of STATs in transcriptional control and their impact on cellular function.pdf.
The emerging treatment landscape of targeted therapy in non-small-cell...
152. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. *BMJ* **311**, 899–909 (1995).

153. Pignon, J. P. et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. *J. Clin. Oncol.* **26**, 3552–3559 (2008).

154. Burdett, S. et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. *Cochrane Database Syst Rev.* CD001430, (2015).

155. Kelly, K. et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. *J. Clin. Oncol.* **33**, 4007–4014 (2015).

156. Shepherd, F., A. N. E. E. A. N. K. et al. Common and rare EGFR mutations (EGFRm) in the RADIANT trial: final follow-up with 5 year data. *J. Clin. Oncol.* **33** abstr 7539 (2015).

157. Pennell, N., C. J. E. et al. SELECT: a multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. *J. Clin. Oncol.* **32** abstr 7514 (2014).

158. Janjigian, Y. Y. et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. *J. Thorac. Oncol.* **6**, 569–575 (2011).

159. Zhong, W. Z. et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG104): a randomised, open-label, phase 3 study. *Lancet Oncol.* **19**, 139–148 (2018).

160. Govindan, R. et al. ALCHEMIST trials: a golden opportunity to transform outcomes in early-stage non-small cell lung cancer. *Clin. Cancer Res.* **21**, 5439–5444 (2015).

161. Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. *N. Engl. J. Med.* **377**, 1919–1929 (2017).

162. Forde, P. M. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. *N. Engl. J. Med.* **378**, 1976–1986 (2018).

163. Yeh, J., Marrone, K. A. & Forde, P. M. Neoadjuvant and consolidation immunology therapy in stage III non-small cell lung cancer. *J. Thorac. Dis.* **10**, 5451–5459 (2018).

164. Murtuza, A. et al. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. *Cancer Res.* **79**, 689–698 (2019).

165. Gerber, D. E. et al. Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). *Clin Lung Cancer* **18**, 333–339 (2017).